Darktrace was founded in 2013 by mathematicians from the University of Cambridge and government cyber intelligence experts in the US and the UK.
Darktrace’s technology, the Enterprise Immune System, applies AI to the cyber defense challenge for the first time, and has proven itself successful in detecting cyber-threats that existing, legacy systems cannot.
In 2016, Darktrace’s leadership in AI was reinforced with the launch of the first-ever autonomous response technology, Darktrace Antigena. This innovation allowed the Enterprise Immune System to react to in-progress cyber-attacks in a highly precise way, giving security teams the time they desperately need to catch up.
When WannaCry ransomware attacks hit hundreds of organizations in 2017, Darktrace Antigena reacted in seconds, protecting customer networks from the inestimable damage.
The company has 40 offices globally and over 900 employees. It is privately owned, with investors including KKR, Summit Partners, Vitruvian Partners, Samsung Ventures, TenEleven Ventures, Hoxton Ventures, Talis Capital, Invoke Capital and Insight Venture Partners.
Darktrace raised $50m in a Series E round in 2018 to hoist its valuation to $1.65 billion. The round was led by Vitruvian Partners with participation from existing investors KKR and 1011 Ventures.